Navigation Links
Mast Therapeutics Reports Third Quarter 2013 Financial Results
Date:11/4/2013

SAN DIEGO, Nov. 4, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended September 30, 2013.

Brian M. Culley, Chief Executive Officer, said: "We continue to focus on EPIC, our pivotal phase 3 study of MST-188 in sickle cell disease.  We almost doubled the number of open clinical sites since the end of the second quarter and are approaching our goal of opening 40 clinical sites in the U.S. Beginning next year, we also plan to open approximately 30 clinical sites outside the U.S."

Mr. Culley continued: "In addition to sickle cell disease, we are evaluating MST-188 in other areas of significant unmet medical need and plan to initiate a 60-patient phase 2 study in acute limb ischemia in early 2014.  This study will determine whether MST-188 improves the effectiveness of existing thrombolytic agents, such as Activase®, a tissue plasminogen activator (tPA) that is approved to treat stroke, heart attack and pulmonary embolism.  If our phase 2 study demonstrates that MST-188 improves the 'clot busting' activity of tPA, we believe it will open the door to developing MST-188 in combination with tPA in all settings in which thrombolytics are used, most notably stroke." 

Third Quarter 2013 Operating ResultsThe Company's net loss for the third quarter of 2013 was $5.3 million, or $0.05 per share (basic and diluted), compared to a net loss of $3.2 million, or $0.07 per share (basic and diluted), for the same period in 2012.

Research and development (R&D) expenses for the third quarter of 2013 were $3.1 million, an increase of $1.4 million, or 87%, compared to $1.7 million for the same period in 2012. The increase was primarily due to increases of $1.3 million in external clinical study fees and expenses and $
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
2. Echo Therapeutics Schedules Third Quarter 2013 Financial Results for Thursday, November 7, 2013
3. G1 Therapeutics to Present at Southeast BIO Investor & Partnering Forum
4. Cell Therapeutics Reports Third Quarter 2013 Financial Results
5. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
6. Abide Therapeutics Appoints Dr. Gary ONeill as Vice President of Biology
7. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
8. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
9. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
10. ISSYS Inc. will showcase its Titan Wireless Implantable Hemodynamic Monitor and its clinical study summary at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference (Booth 1638) in San Francisco (October 29 to 31, 2013)
11. Aratana Therapeutics Adds to Commercial Leadership Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Pa. , Jan. 23, 2015  MedScope ( www.medscope.org ... been nominated for a 2015 Connected World ... Emergency Response System (mPERS), that can be used anywhere, ... technology partner.  In nominating MedScope, ...
(Date:1/23/2015)... /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential ... ("Advaxis" or the "Company") (NASDAQ: ADXS ), ... to shareholders. On January 21, 2015, an ... Advaxis had misrepresented the clinical data for its ADXS-HPV ...
(Date:1/23/2015)... Idaho , Jan. 23, 2015  Now available for ... No. 7,849,611) support that prevents ankle sprains by cushioning ... brace, it fits securely around the outside of any ... mobility & comfort while still offering protection against sprains. ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
(Date:1/22/2015)... 2015 Deer Path of Huntley -- ... Day Happy Hour from 3 p.m. to 4 p.m. on Feb. ... in Huntley, Illinois, serves adults with physical disabilities between the ages ... Valentine's Day treats, games and sweetheart-themed karaoke. , For more information ...
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently ... thrilled to have it lead the wedding dress industry into ... prom dresses for the global market. , “The CEO of ... he focuses on continuing the goal of operational excellence and ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... actually be able to find a doctor when you get old! ... do for other small businesses. 8. Grandma will thank you. ... Top Ten reasons why Congress should repeal the SGR (sustainable growth ... over the next week, with the #1 reason to be made ...
... rhesus monkeys lost on average 11 percent of their body ... that selectively destroys the blood supply of fat tissue, a ... MD Anderson Cancer Center reports in Science Translational Medicine ... (waistline) also were reduced, while all three measures were unchanged ...
... way breast cancer characteristics are evaluated and categorized has ... a microscope. Pathologists examine the tumors visually and score ... ago. These scores help doctors assess the type and ... patient,s prognosis and course of treatment. In a ...
... , WEDNESDAY, Nov. 9 (HealthDay News) -- A number of ... by researchers. The study included 177 children in 12 ... times a year from kindergarten through fifth grade. The ... concept of exact numerical quantities -- for example, that the ...
... (HealthDay News) -- A new study suggests that the ... a precancerous lesion that is often a forerunner to ... against human papillomavirus (HPV) types 16 and 18, which ... particularly effective when given to adolescent girls before they ...
... 9 (HealthDay News) -- Doctors should appeal to young people,s ... U.S. Preventive Services Task Force says in draft recommendations released ... how too much sun exposure can affect their looks now ... warning them they,re at risk for skin cancer years from ...
Cached Medicine News:Health News:Obese monkeys lose weight on drug that attacks blood supply of fat cells 2Health News:Obese monkeys lose weight on drug that attacks blood supply of fat cells 3Health News:Obese monkeys lose weight on drug that attacks blood supply of fat cells 4Health News:Stanford team trains computer to evaluate breast cancer 2Health News:Stanford team trains computer to evaluate breast cancer 3Health News:Study Spots Early Signs of Math Disabilities in Kids 2Health News:More Evidence That HPV Vaccine Shields Against Cervical Cancer 2Health News:Use Vanity to Reduce Young People's Sun Exposure: Task Force 2Health News:Use Vanity to Reduce Young People's Sun Exposure: Task Force 3
The Embla 384 cell washer is a top-loading, robotic-compatible microplate washer for high throughput screening. It is designed specifically for cell-based assays, which require a gentler wash, but ca...
Lab-Reader...
Elisa Plate Reader...
Fully automatic NRTL and CE certified microplate reader....
Medicine Products: